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Abstract
The goal of complete remission (CR) in acute leukemias could be achieved with 
intensive induction chemotherapy however patients need post remission consolida-
tion strategies such as high-dose chemotherapy, or autologous (ASCT) or allogeneic 
(allo-SCT) hematopoetic stem cell transplantation for durable response. However, 
Allo-SCT is getting more attention in last decades because of improvements of 
conditioning regimens and graft versus host disease (GVHD) prohylaxis strategies 
and alternatively available donor sources, it is not suitable for all leukemia patients. 
The patients who would benefit from Allo-SCT or ASCT could be defined more 
easily by using risk stratification systems and minimal residual disease (MRD) 
monitoring. ASCT is considered a treatment option even if its use is declining in the 
world. Herein, we tried to summarize the studies that report the outcomes of ASCT 
in acute myeloid leukemia (AML) and acute, lymphoblastic leukemia and describe 
the patients who would be good candidate for ASCT.
Keywords: autologous stem cell, transplantation, acute leukemia, adult, 
lymphoblastic leukemia, myeloid leukemia
1. Introduction
Standard chemotherapy regimens are the first step for the treatment of acute 
leukemias. However, the complete remission could be achieved with intensive 
chemotherapy, durable remission is not common and patients will relapse within 
months unless additional therapy is given. There is an extensive debate about 
post remission therapy. There is no consensus about intensive chemotherapy as a 
consolidation and/or stem cell transplantation (SCT) after first remission (CR1). 
Allogeneic stem cell transplantation (Allo-SCT) for acute leukemias has been 
increased due to the developments of allo-SCT techniques. Availability of alter-
native donor sources (including haploidentical, matched unrelated donors and 
umbilical cord blood), improvements of graft versus host disease (GVHD) prophy-
laxis strategies and reduced-intensity conditioning (RIC) regimens are developed 
in last decades and Allo-SCT has been used widely all over the world. However, 
lower incidence of relapse rates after allo-SCT because of graft versus leukemia 
effect makes allo-SCT more popular, high morbidity rates due to chronic GVHD, 
secondary graft failure and high treatment related mortality (TRM) rates in the 
patients who underwent Allo-SCT should be considered and it is not recommended 
for the patients with good risk. Allo-SCT is not available for elderly patients and 
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the patients who do not have HLA-matched related or unrelated donor. Autologous 
stem cell transplantation (ASCT) is an alternative and valuable treatment option 
with acceptable long term outcomes and lower TRM rates for the patients with low 
and intermediate risk after CR1 and the patients who are not eligible for Allo-SCT. 
Center for International Blood and Marrow Transplantation Research (CIBMTR) 
showed the rates of ASCT and Allo-SCT in acute myeloid leukemia (AML) and 
acute lymphoblastic leukemia (ALL) in the USA (Figure 1).
2. ASCT for acute myeloid leukemia
More than half of AML patients achieved complete remission after standard 
induction therapy but 60–70% of patients will relapse without consolidation 
therapy. ASCT, an effective therapy for AML was started to use in 1980’s for con-
solidation in AML patients [1–5]. Since then, it is a challenge to define the patients 
who would benefit from ASCT. Bone marrow (BM) initially preferred source of 
stem cells for ASCT. After hematopoietic growth factors provided the possibility to 
use peripheral blood stem cells (PBSC) grafts after intensive chemotherapy courses 
since 1994, the treatment compliance of ASCT has improved and the treatment-
related mortality (TRM) has been reduced due to accelerated hematopoietic 
reconstitution [6]. Mobilized PBCS have replaced bone marrow because of the 
main advantages of PBSCs as a stem cell source are markedly faster neutrophil and 
platelet recovery times than bone marrow, with consequently reduced infection, 
bleeding and hospitalization risks. The PBSC target dose is considered an amount 
of CD34+ cells ≥2 × 106/kg body weight. There is numerous clinical studies compare 
ASCT with chemotherapy or Allo-SCT in AML patients according to cytogenetic 
risk groups and CR1 or second remission (CR2). National Comprehensive Cancer 
Network (NCCN) and European leukemia network (ELN) divided patients with 
AML into three risk status groups: good/favorable, intermediate, and poor/adverse 
risk by genetic abnormality in 2017 (Table 1) [7]. The ‘favorable’ group includes 
patients with either inv.(16), t(16;16), t(8; 21), mutated NPM1 without FLT3 
Figure 1. 
The rates of autologous stem cell transplantation (ASCT) and allogeneic stem cell transplantation in acute 
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)*. (*Data presented in table is kindly 
provided by CIBMTR).
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ITD (internal tandem duplications) (NPM+/FLT3 ITD−) or mutated CEBPA. An 
‘adverse’ group consists of patients with inv. (3) or t (3;3), t(6;9), t(v;11) either −5 
or del (5q), −7, abn (17p) or ⩾3 cytogenetic abnormalities not including transloca-
tions (complex karyotype). An intermediate-1 group comprises patients with a nor-
mal karyotype (NK) and with the other genotypic combinations of NPM1 and FLT3 
ITD (+/+, −/−, −/+) and an intermediate-2 group consists of patients with t (9;11) 
and cytogenetic abnormalities not noted above. Good-risk AML patients qualify for 
chemotherapeutic consolidation, but recent reports suggested favorable outcome 
for good-risk patients with ASCT, which provides a possible option in that category 
of patients [8, 9]. The survival outcomes of patients with good-risk or intermediate-
risk AML who underwent ASCT as postremission therapy were favorable—prob-
ably due to the use of PBSC rather than instead of BM, which may decrease the risk 
of transplant-related complications—but that the survival outcomes of similarly 
treated poor-risk AML patients were not.
Gruppo Italiano Trapianto di Midollo Osseo (GITMO) analyzed 809 AML 
patients who were autografted in CR1 retrospectively [10]. Two year leukemia free 
survival (LFS) and Overall Survival (OS) rates were found 51% and 65%, respec-
tively and it was reported that survival was significantly influenced by cytogenetic 
risk. Patients with good risk group had remarkable better outcomes in this study. 
The 2 year cumulative incidence of relapse was higher in poor risk patients (28 ± 7% 
for good risk group vs. 48 ± 8% for poor risk group, p < 0,0002). Patients with 
CEBPA double mutated (CEBPAdm) and nucleophosmin-1 (NPM) mutated AML 
have better outcome with ASCT [9, 11]. It has been already demonstrated that the 
subset of patients with NPM1+ mutations without fms-related tyrosine kinase 3 
gene (FLT3) internal tandem duplications (FLT3-ITD) derive no survival benefit 
from allo-SCT [12].
Risk category Cytogenetic abnormality
Favorable t(8;21)(q22;q22): RUNX1-RUNX1T1
inv(16)(p13.1q22) or t(16;16)(p13.1;q22): CBFB-MYH11
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow
Biallelic mutated CEBPA
Intermediate Mutated NPM1 and FLT3-ITDhigh
Wild type NPM1 without FLT3-ITD or with FLT3-ITDlow
t(9;11)(p21.3;q23.3); MLLT3-KMT2A











Genetic risk stratification according to the ELN-2017.
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Several historical randomized trials have reported that ASCT can significantly 
reduce the relapse rates compare with conventional chemotherapy alone. The study 
performed by the Dutch–Belgian Hemato-Oncology Cooperative Group/Swiss 
Group for Clinical Cancer Research (HOVON-SAKK) Cooperative Consortium 
compared the outcomes of ASCT with chemotherapy including 517 patients who 
were randomly recorded between 1995 and 2006 [1]. Rates of relapse after chemo-
therapy vs. after ASCT were 70% vs. 58%, respectively (P = .02), 5 year follow up 
and no significant difference in LFS of 29% vs. 38% (P = .065). OS did not differ 
between these two groups and was estimated to be 41% vs. 44%, respectively, at 
5 years from randomization. TRM was higher in ASCT group than chemotherapy 
group (4% vs. 1% respectively).
A meta-analysis which included 11 studies compared survival outcomes of 
alloSCT from matched sibling donor (MSD) or matched unrelated donor (MUD) 
versus ASCT in intermediate-risk AML and demonstrated alloSCT from MSDs 
rather than MUDs was associated with better OS than that with ASCT [13] however 
recent retrospective trials reported similar survival rates for AML patients who 
underwent autoSCT and allo-SCT from MSDs and MUDs [3, 14, 15].
The treatment options are not well defined in older patients with leukemia. 
Higher incidence of AML secondary to previous myelodysplastic syndrome (MDS), 
adverse mutation pattern and karyotype and poor performance status are the 
reasons of poor outcomes in older AML patients [16–18]. They usually do not have 
MSD and available regimens are limited due to many of comorbidities especially 
cardiovasculary disease. ASCT may be used in patients up to age 70 years with an 
acceptable TRM of approximately 8%, which compares favorably to 17% as was 
observed after RIC alloHSCT.
Several reports from EBMT and CIBMTR showed long-term leukemia free 
survival (LFS) rates are 45–55% in patients transplanted in CR 1 and 25–35% for those 
transplanted in CR2 [19–21]. The patients who are not eligible for Allo-SCT ASCT 
may be an acceptable post-remission therapy in CR1 [14]. Allo-SCT still remains first 
line treatment for poor risk patients while ASCT is getting attention for good risk and 
especially intermediate risk patients who have favorable prognostic factors, including  
MRD negativity after the imitation of induction chemotherapy, a WBC count of 
<20,000/μL at time of the diagnosis, an FAB classification of M1–5, and ≥ 50% MPO 
positivity. Decision-making might benefit from taking minimal residual disease 
(MRD) into account [22, 23]. Real-time quantitative PCR (qPCR) and multiparameter 
flow cytometry (MFC) are effective techniques for monitoring MRD before and after 
ASCT in patients with AML, and MRD status pre-ASCT is an independent prognostic 
factor for both OS and LFS after ASCT [24, 25]. Whereby MRD-negative patients may 
be consolidated by ASCT and MRD-positive patients may proceed to allo-SCT. ASCT 
is generating new interest, especially in intermediate-risk patients who became MRD 
negative upon induction chemotherapy [26].
The traditional conditioning regimens before ASCT that are mostly myeloabla-
tive and based on busulfan; combination of busulfan/ cyclophosphamide (BUCY), 
busulfan/etoposide, cyclophosphamide/Total body irradiation (TBI), Busulfan/
high dose melphalan. Different regimens such as modifications of the BCNU, 
etoposide, cytarabine, melphalan (BEAM) regimen, busulfan/etoposide/ cyta-
rabine, TBI/cytarabine/melphalan could be used in different centers. Three large 
retrospective studies showed that busulfan/high dose melphalan regimen has better 
outcomes than BUCY [27–29]. Although both oral and intravenous busulfan were 
used in various regimens, it has become clear that the intravenous administration of 
busulfan should be preferred because of fewer complications [30]. Favorable long-
term LFS after auto-SCT using a high-dose cytarabine-containing regimen has been 
showed. The most common treatment related complication of ASCT is mucositis 
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and mucositis are usually more frequent in the patients who were treated with oral 
busulfan than ıv busulfan.
3. ASCT for acute promyelocytic leukemia
Acute promyelocytic leukemia (APL) accounts 10–15% of AML in adults. It 
is highly curable disease and remission is achieved in 90% of APL patients after 
anthracycline-based induction therapy plus ATRA and recently arsenic trioxide 
(ATO). The combination of ATRA and anthracyclines remains the gold standard 
for high risk patients. There is not a role for stem cell transplantation in APL in 
CR1, independently from any initial risk category. ELN suggested that patients who 
relapsed after ATRA plus chemotherapy should be treated with an ATRA plus ATO 
based approach as salvage therapy until achievement of MRD negativity. Despite 
of SCT is accepted treatment for the 10–20% patients who relapsed, the choice of 
ASCT vs. Allo-SCT remains controversial.
EBMT reviewed 625 APL patients transplanted ASCT or Allo-SCT, lower relapse 
rates and higher 5 year LFS reported in Allo-SCT group. Although TRM was higher 
in Allo-SCT patients, Allo-SCT was recommended in CR2 when a sibling donor 
was available in this study [31]. Holter et al. reported OS was better after ASCT 
than after chemotherapy and ATO. ASCT was the preferred therapy for patients 
with CR2 status, and survival outcomes were superior in patients who received 
ASCT compared with those who received ATO-based consolidation therapy [32]. 
Besides ASCT is superior than allo-SCT in relapsed APL due to low TRM and 
durable remission, pre-SCT bone marrow cytogenetic and molecularly evaluation 
is important. It was recommended allogeneic HCT if the pre-HCT marrow was 
cytogenetically or molecularly positive [33]. ASCT is less toxic than allo-SCT, and 
appears equally potent particularly when a negative PML-RARA status is achieved 
before transplantation.
4. ASCT for acute lymphocytic leukemia
ALL is divided into tumors of B cell and T cell lineage and it is the most common 
cause of leukemia in children however up to 20% of the cases of ALL occur in adults. 
Despite of the developments of induction chemotherapy regimen, relapse rates and 
mortality still remain high in this century. Most of studies were designed according to 
risk stratification and categorized patients into standard, intermediate or poor risk. 
Poor risk criteria are cytogenetic abnormalities t(9;22), t(4;11), or t(1;19); pro–B-cell 
immunophenotype; high WBC (i.e., > 30 × 109/L in case of B-ALL; > 100 × 109/L 
in case of T-cell ALL [T-ALL]) at the time of diagnosis. Although the introduction 
of more aggressive chemotherapy regimens has reduced the need for allo-HSCT in 
patients younger than 35 years of age, allo-HSCT remains the standard of care for 
high-risk patients and relapse after CR1. SCT is still a debate in ALL patients with-
out poor-risk features however Allo-SCT is highly recommended in poor risk ALL 
patients in CR1. Allo-SCT is not certainly suggested in ALL patients without poor 
risk to avoid the unnecessary risks of transplantation procedure-related mortality 
and GVHD to patients, who may be cured with chemotherapy alone and to postpone 
allo-SCT to an eventual relapse. The standard risk patients rather than the high-risk 
patients, older patients and the patients who are not eligible for Allo-SCT may be the 
ones who are most likely to benefit from ASCT in first remission. MRD has emerged 




Several studies have been published about the experience of ASCT in ALL. The 
results of some recent trials are summarized in Table 2. Data from three prospective 
trials of the French group have failed to demonstrate any significant superiority of 
ASCT over chemotherapy, even in a subset of high-risk patients [39–41]. Conversely, 
it has been reported that ASCT may be an effective treatment for ALL patients who 
experienced an isolated extramedullary relapse. A recent randomized study of 
433 adult standard risk ALL patients showed that LFS at 5 years was significantly 
better in patients who underwent allo-HSCT compared with ASCT (60% vs. 42%, 
P = 0.01). In a large study which is comparing chemotherapy and autologous trans-
plantation in ALL patients, the LFS and OS were found superior for chemotherapy 
group [34]. In the LALA-87 trial, results in standard-risk ALL were similar for 
Allo-SCT [37] and for chemotherapy or ASCT and then the same group reported no 
benefit of ASCT for ALL in all risk groups [42].
The Philadelphia chromosome (Ph) translocation (9; 22) is the most common 






Goldstone et al. 
2008 [34]









5-year OS is better 
in donor group, 53% 
versus 45% (P = .01), 
and lower the relapse 
rate in donor group 
(P < or = .001)
OS is better in 
Chemotherapy 
group than ASCT 
group (46% [95% 
CI = 39–53%] 
vs. 37% [95% 
CI = 31–44%]; 
P = .03)
Thomas et al. 
2004 (LALA94 
study) [35]
922 1994–2002 15–55 ASCT vs. 
chemotherapy
ASCT did not show 
superiority over 
chemotherapy 
in high-risk ALL 
patients.
Hunault 
et al. 2003 
(GOELAMS) [36]
198 1994–1998 15–59 Allo-SCT vs. 
ASCT
OS and LFS is 
better in Allo-SCT 
(75% vs. 39% 
P = .0027 and 72% 
vs. 32% P = .0004 
respectively) relapse 
rates higher in ASCT
Fiere et al.  
1993 [37]




benefit of ASCT over 
chemotherapy
Powles et al.  
2002 [38]
77 1984–1998 16–59 All patients 
underwent 
ASCT
10-year LFS and 
OS rates are 50% 
(95% CI, 38–62%) 
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in 2 to 5% of children with ALL and 30% percent of adults. Historically, Ph-positive 
ALL (Ph + ALL) was considered a very high-risk subtype and Allo-SCT was highly 
recommended for all eligible patients. After the introduction of tyrosine kinase 
inhibitors (TKIs) (first TKI, imatinib; second-generation TKIs such as dasatinib or 
nilotinib; the third-generation TKI, ponatinib) which could be successfully used 
both as salvage therapy and upfront in combination with intensive chemotherapy, 
complete remission is achieved in 90% of Ph + ALL patients [43]. The critical role 
of MRD prior to ASCT was already confirmed in Ph-negative ALL and may also be 
important in the Ph + setting [44]. Results of ASCT for Ph + ALL improved mark-
edly in recent years with more than half of patients being alive and leukemia-free 
at 2 years [43, 45, 46]. The role of biologic response modifiers such as α-interferon 
(α-IFN and interleukin-2) in Ph + ALL is analyzed and it was reported that combi-
nation of α-IFN with maintenance chemotherapy and ASCT improves the outcomes 
in Ph + ALL [47, 48].
5. Conclusion
According to NCCN guidelines; Patients with good-risk AML are recommended 
to undergo high-dose cytarabine-based chemotherapy. Patients with poor-risk 
AML are recommended to undergo allogeneic stem cell transplantation (alloSCT). 
However, the best post remission therapy for patients with intermediate-risk AML 
in first complete remission (AML/CR1) is still uncertain. ASCT would be an option 
in CR1 and MRD negative. ASCT is a kind of standard treatment of CR2 in APL 
patients. There is no benefit of ASCT in Ph negative ALL patients however ASCT 
is a therapeutic option for relapsed Ph + ALL. Although the main disadvantages of 
ASCT are the possibility of contamination of leukemic cells in the stem cell product 
and the absence of graft-versus-leukemia effect, which lead to a higher relapse 
rates than that of Allo-SCT, ASCT should be considered a standard therapy in acute 
leukemia patients who are not eligible Allo-SCT and MRD negative in CR1 and the 
patients without poor risk.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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